Edwards Lifesciences
Edwards Lifesciences Corporation, a leader in heart valve technology and critical care monitoring, is headquartered in the United States. Founded in 1958, the company has established itself as a pioneer in the medical device industry, particularly in the development of innovative solutions for structural heart disease and advanced haemodynamic monitoring. With a strong presence in North America, Europe, and Asia, Edwards Lifesciences is renowned for its core products, including transcatheter heart valves and surgical heart valves, which are distinguished by their unique design and efficacy. The company has achieved significant milestones, such as the first FDA approval for a transcatheter aortic valve replacement, solidifying its market position as a trusted provider in cardiovascular care. Edwards Lifesciences continues to drive advancements in patient outcomes through its commitment to innovation and excellence in healthcare.
DitchCarbon Score
How does Edwards Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Edwards Lifesciences's score of 45 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Edwards Lifesciences's reported carbon emissions
In 2023, Edwards Lifesciences reported total greenhouse gas emissions of approximately 571,389,000 kg CO2e, with 16,120,000 kg CO2e from Scope 1, 23,783,000 kg CO2e from Scope 2, and 571,389,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 42% by 2030 from a 2021 baseline. Additionally, they plan to decrease Scope 3 emissions by 51.6% per USD of value added within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit warming to 1.5°C. Edwards Lifesciences is headquartered in the United States and operates within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 4,977,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 23,498,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Edwards Lifesciences is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
